 | • レポートコード：QYR2104Z4964 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、再発性多形性膠芽腫治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（AU-105、アキシチニブ、AXL-1717、AZD-7451、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・再発性多形性膠芽腫治療の市場動向 ・企業の競争状況、市場シェア ・再発性多形性膠芽腫治療の種類別市場規模（AU-105、アキシチニブ、AXL-1717、AZD-7451、その他） ・再発性多形性膠芽腫治療の用途別市場規模（病院、診療所、その他） ・再発性多形性膠芽腫治療の北米市場規模2016-2027（アメリカ、カナダ） ・再発性多形性膠芽腫治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・再発性多形性膠芽腫治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・再発性多形性膠芽腫治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・再発性多形性膠芽腫治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Boehringer Ingelheim GmbH、Boston Biomedical, Inc.、Bristol-Myers Squibb Company、Cantex Pharmaceuticals, Inc.、Cavion LLC、Celldex Therapeutics, Inc.、Coherus BioSciences, Inc.、Cortice Biosciences, Inc.、Eisai、Eli Lilly and Company、EnGeneIC Ltd、ERC Belgium SA、GenSpera, Inc.、Genzyme Corporation、GW Pharmaceuticals Plc、ImmunoCellular Therapeutics, Ltd.） ・結論 |
Market Analysis and Insights: Global Recurrent Glioblastoma Multiforme Treatment Market
The global Recurrent Glioblastoma Multiforme Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recurrent Glioblastoma Multiforme Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Recurrent Glioblastoma Multiforme Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Recurrent Glioblastoma Multiforme Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Recurrent Glioblastoma Multiforme Treatment market.
Global Recurrent Glioblastoma Multiforme Treatment Scope and Market Size
Recurrent Glioblastoma Multiforme Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recurrent Glioblastoma Multiforme Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
AU-105
Axitinib
AXL-1717
AZD-7451
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cantex Pharmaceuticals, Inc.
Cavion LLC
Celldex Therapeutics, Inc.
Coherus BioSciences, Inc.
Cortice Biosciences, Inc.
Eisai
Cantex Pharmaceuticals, Inc.
Cavion LLC
ERC Belgium SA
GenSpera, Inc.
Genzyme Corporation
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 AU-105
1.2.3 Axitinib
1.2.4 AXL-1717
1.2.5 AZD-7451
1.2.6 Others
1.3 Market by Application
1.3.1 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Perspective (2016-2027)
2.2 Recurrent Glioblastoma Multiforme Treatment Growth Trends by Regions
2.2.1 Recurrent Glioblastoma Multiforme Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Recurrent Glioblastoma Multiforme Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Recurrent Glioblastoma Multiforme Treatment Industry Dynamic
2.3.1 Recurrent Glioblastoma Multiforme Treatment Market Trends
2.3.2 Recurrent Glioblastoma Multiforme Treatment Market Drivers
2.3.3 Recurrent Glioblastoma Multiforme Treatment Market Challenges
2.3.4 Recurrent Glioblastoma Multiforme Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Revenue
3.1.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Revenue (2016-2021)
3.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme Treatment Revenue
3.4 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio
3.4.1 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme Treatment Revenue in 2020
3.5 Recurrent Glioblastoma Multiforme Treatment Key Players Head office and Area Served
3.6 Key Players Recurrent Glioblastoma Multiforme Treatment Product Solution and Service
3.7 Date of Enter into Recurrent Glioblastoma Multiforme Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Type
4.1 Global Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Type (2016-2021)
4.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2022-2027)
5 Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Application
5.1 Global Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Application (2016-2021)
5.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size (2016-2027)
6.2 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type
6.2.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
6.2.2 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
6.2.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
6.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application
6.3.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
6.3.2 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
6.3.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
6.4 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country
6.4.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
6.4.2 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size (2016-2027)
7.2 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type
7.2.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
7.2.2 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
7.2.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
7.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application
7.3.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
7.3.2 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
7.3.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
7.4 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country
7.4.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
7.4.2 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size (2016-2027)
8.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type
8.2.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application
8.3.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region
8.4.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size (2016-2027)
9.2 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type
9.2.1 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
9.3 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application
9.3.1 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
9.4 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country
9.4.1 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size (2016-2027)
10.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type
10.2.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application
10.3.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country
10.4.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim GmbH
11.1.1 Boehringer Ingelheim GmbH Company Details
11.1.2 Boehringer Ingelheim GmbH Business Overview
11.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Introduction
11.1.4 Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.1.5 Boehringer Ingelheim GmbH Recent Development
11.2 Boston Biomedical, Inc.
11.2.1 Boston Biomedical, Inc. Company Details
11.2.2 Boston Biomedical, Inc. Business Overview
11.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.2.4 Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.2.5 Boston Biomedical, Inc. Recent Development
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Details
11.3.2 Bristol-Myers Squibb Company Business Overview
11.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Introduction
11.3.4 Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.3.5 Bristol-Myers Squibb Company Recent Development
11.4 Cantex Pharmaceuticals, Inc.
11.4.1 Cantex Pharmaceuticals, Inc. Company Details
11.4.2 Cantex Pharmaceuticals, Inc. Business Overview
11.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.4.4 Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.4.5 Cantex Pharmaceuticals, Inc. Recent Development
11.5 Cavion LLC
11.5.1 Cavion LLC Company Details
11.5.2 Cavion LLC Business Overview
11.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Introduction
11.5.4 Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.5.5 Cavion LLC Recent Development
11.6 Celldex Therapeutics, Inc.
11.6.1 Celldex Therapeutics, Inc. Company Details
11.6.2 Celldex Therapeutics, Inc. Business Overview
11.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.6.4 Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.6.5 Celldex Therapeutics, Inc. Recent Development
11.7 Coherus BioSciences, Inc.
11.7.1 Coherus BioSciences, Inc. Company Details
11.7.2 Coherus BioSciences, Inc. Business Overview
11.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.7.4 Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.7.5 Coherus BioSciences, Inc. Recent Development
11.8 Cortice Biosciences, Inc.
11.8.1 Cortice Biosciences, Inc. Company Details
11.8.2 Cortice Biosciences, Inc. Business Overview
11.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.8.4 Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.8.5 Cortice Biosciences, Inc. Recent Development
11.9 Eisai
11.9.1 Eisai Company Details
11.9.2 Eisai Business Overview
11.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Introduction
11.9.4 Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.9.5 Eisai Recent Development
11.10 Eli Lilly and Company
11.10.1 Eli Lilly and Company Company Details
11.10.2 Eli Lilly and Company Business Overview
11.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Introduction
11.10.4 Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.10.5 Eli Lilly and Company Recent Development
11.11 EnGeneIC Ltd
11.11.1 EnGeneIC Ltd Company Details
11.11.2 EnGeneIC Ltd Business Overview
11.11.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Introduction
11.11.4 EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.11.5 EnGeneIC Ltd Recent Development
11.12 ERC Belgium SA
11.12.1 ERC Belgium SA Company Details
11.12.2 ERC Belgium SA Business Overview
11.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Introduction
11.12.4 ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.12.5 ERC Belgium SA Recent Development
11.13 GenSpera, Inc.
11.13.1 GenSpera, Inc. Company Details
11.13.2 GenSpera, Inc. Business Overview
11.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.13.4 GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.13.5 GenSpera, Inc. Recent Development
11.14 Genzyme Corporation
11.14.1 Genzyme Corporation Company Details
11.14.2 Genzyme Corporation Business Overview
11.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Introduction
11.14.4 Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.14.5 Genzyme Corporation Recent Development
11.15 GW Pharmaceuticals Plc
11.15.1 GW Pharmaceuticals Plc Company Details
11.15.2 GW Pharmaceuticals Plc Business Overview
11.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Introduction
11.15.4 GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.15.5 GW Pharmaceuticals Plc Recent Development
11.16 ImmunoCellular Therapeutics, Ltd.
11.16.1 ImmunoCellular Therapeutics, Ltd. Company Details
11.16.2 ImmunoCellular Therapeutics, Ltd. Business Overview
11.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Introduction
11.16.4 ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.16.5 ImmunoCellular Therapeutics, Ltd. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of AU-105
Table 3. Key Players of Axitinib
Table 4. Key Players of AXL-1717
Table 5. Key Players of AZD-7451
Table 6. Key Players of Others
Table 7. Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2016-2021)
Table 11. Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2022-2027)
Table 13. Recurrent Glioblastoma Multiforme Treatment Market Trends
Table 14. Recurrent Glioblastoma Multiforme Treatment Market Drivers
Table 15. Recurrent Glioblastoma Multiforme Treatment Market Challenges
Table 16. Recurrent Glioblastoma Multiforme Treatment Market Restraints
Table 17. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Players (2016-2021)
Table 19. Global Top Recurrent Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme Treatment as of 2020)
Table 20. Ranking of Global Top Recurrent Glioblastoma Multiforme Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Recurrent Glioblastoma Multiforme Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Recurrent Glioblastoma Multiforme Treatment Product Solution and Service
Table 24. Date of Enter into Recurrent Glioblastoma Multiforme Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Recurrent Glioblastoma Multiforme Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Boehringer Ingelheim GmbH Company Details
Table 65. Boehringer Ingelheim GmbH Business Overview
Table 66. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product
Table 67. Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 68. Boehringer Ingelheim GmbH Recent Development
Table 69. Boston Biomedical, Inc. Company Details
Table 70. Boston Biomedical, Inc. Business Overview
Table 71. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Product
Table 72. Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 73. Boston Biomedical, Inc. Recent Development
Table 74. Bristol-Myers Squibb Company Company Details
Table 75. Bristol-Myers Squibb Company Business Overview
Table 76. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product
Table 77. Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 78. Bristol-Myers Squibb Company Recent Development
Table 79. Cantex Pharmaceuticals, Inc. Company Details
Table 80. Cantex Pharmaceuticals, Inc. Business Overview
Table 81. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Product
Table 82. Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 83. Cantex Pharmaceuticals, Inc. Recent Development
Table 84. Cavion LLC Company Details
Table 85. Cavion LLC Business Overview
Table 86. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product
Table 87. Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 88. Cavion LLC Recent Development
Table 89. Celldex Therapeutics, Inc. Company Details
Table 90. Celldex Therapeutics, Inc. Business Overview
Table 91. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Product
Table 92. Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 93. Celldex Therapeutics, Inc. Recent Development
Table 94. Coherus BioSciences, Inc. Company Details
Table 95. Coherus BioSciences, Inc. Business Overview
Table 96. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product
Table 97. Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 98. Coherus BioSciences, Inc. Recent Development
Table 99. Cortice Biosciences, Inc. Company Details
Table 100. Cortice Biosciences, Inc. Business Overview
Table 101. Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 102. Cortice Biosciences, Inc. Recent Development
Table 103. Eisai Company Details
Table 104. Eisai Business Overview
Table 105. Eisai Recurrent Glioblastoma Multiforme Treatment Product
Table 106. Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 107. Eisai Recent Development
Table 108. Eli Lilly and Company Company Details
Table 109. Eli Lilly and Company Business Overview
Table 110. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product
Table 111. Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 112. Eli Lilly and Company Recent Development
Table 113. EnGeneIC Ltd Company Details
Table 114. EnGeneIC Ltd Business Overview
Table 115. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product
Table 116. EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 117. EnGeneIC Ltd Recent Development
Table 118. ERC Belgium SA Company Details
Table 119. ERC Belgium SA Business Overview
Table 120. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product
Table 121. ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 122. ERC Belgium SA Recent Development
Table 123. GenSpera, Inc. Company Details
Table 124. GenSpera, Inc. Business Overview
Table 125. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Product
Table 126. GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 127. GenSpera, Inc. Recent Development
Table 128. Genzyme Corporation Company Details
Table 129. Genzyme Corporation Business Overview
Table 130. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product
Table 131. Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 132. Genzyme Corporation Recent Development
Table 133. GW Pharmaceuticals Plc Company Details
Table 134. GW Pharmaceuticals Plc Business Overview
Table 135. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product
Table 136. GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 137. GW Pharmaceuticals Plc Recent Development
Table 138. ImmunoCellular Therapeutics, Ltd. Company Details
Table 139. ImmunoCellular Therapeutics, Ltd. Business Overview
Table 140. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Product
Table 141. ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 142. ImmunoCellular Therapeutics, Ltd. Recent Development
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Type: 2020 VS 2027
Figure 2. AU-105 Features
Figure 3. Axitinib Features
Figure 4. AXL-1717 Features
Figure 5. AZD-7451 Features
Figure 6. Others Features
Figure 7. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application: 2020 VS 2027
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Recurrent Glioblastoma Multiforme Treatment Report Years Considered
Figure 12. Global Recurrent Glioblastoma Multiforme Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Recurrent Glioblastoma Multiforme Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2022-2027)
Figure 16. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Players in 2020
Figure 17. Global Top Recurrent Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Recurrent Glioblastoma Multiforme Treatment Revenue in 2020
Figure 19. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 23. North America Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 24. North America Recurrent Glioblastoma Multiforme Treatment Market Share by Country (2016-2027)
Figure 25. United States Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 29. Europe Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 30. Europe Recurrent Glioblastoma Multiforme Treatment Market Share by Country (2016-2027)
Figure 31. Germany Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Share by Region (2016-2027)
Figure 41. China Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Recurrent Glioblastoma Multiforme Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Boehringer Ingelheim GmbH Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 61. Boston Biomedical, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 62. Bristol-Myers Squibb Company Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 63. Cantex Pharmaceuticals, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 64. Cavion LLC Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 65. Celldex Therapeutics, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 66. Coherus BioSciences, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 67. Cortice Biosciences, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 68. Eisai Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 69. Eli Lilly and Company Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 70. EnGeneIC Ltd Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 71. ERC Belgium SA Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 72. GenSpera, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 73. Genzyme Corporation Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 74. GW Pharmaceuticals Plc Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 75. ImmunoCellular Therapeutics, Ltd. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
世界の再発性多形性膠芽腫（GBM）治療市場規模・現状・予測（2021年-2027年） Recurrent glioblastoma multiforme is the most aggressive cancer that begins within the brain. The increasing incidence of seizure is expected to drive the recurrent glioblastoma multiforme treatment market. Market Analysis and Insights: Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market…- 世界の多形性膠芽腫治療（GBM）市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Glioblastoma Multiforme Treatment (GBM) Market The global Glioblastoma Multiforme Treatment (GBM) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis…
- 世界の多形性膠芽腫治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Glioblastoma Multiforme Treatment Market The global Glioblastoma Multiforme Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high da…
- 世界の多形性膠芽腫（GBM）治療市場規模・現状・予測（2021年-2027年） Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pip…
- 世界の網膜芽細胞腫治療市場規模・現状・予測（2021年-2027年） Retinoblastoma is a cancer that starts in the retina, the very back part of the eye. Market Analysis and Insights: Global Retinoblastoma Treatment Market The global Retinoblastoma Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during…